ARCH Venture Management as of June 30, 2025
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 11 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Beam Therapeutics (BEAM) | 25.8 | $77M | 4.5M | 17.01 | |
| Vir Biotechnology (VIR) | 21.8 | $65M | 13M | 5.04 | |
| Maze Therapeatics (MAZE) | 16.9 | $51M | 4.1M | 12.28 | |
| Rapport Therapeutics (RAPP) | 14.2 | $42M | 3.7M | 11.38 | |
| Verve Therapeutics (VERV) | 7.5 | $23M | 2.0M | 11.23 | |
| Lyell Immunopharma Com New (LYEL) | 5.4 | $16M | 1.8M | 8.85 | |
| Erasca (ERAS) | 4.7 | $14M | 11M | 1.27 | |
| Gossamer Bio (GOSS) | 3.3 | $9.9M | 8.1M | 1.23 | |
| Q32 Bio (QTTB) | 0.2 | $478k | 321k | 1.49 | |
| Unity Biotechnology Com New | 0.1 | $386k | 1.0M | 0.38 | |
| Cero Therapeutics Hldgs (CERO) | 0.1 | $216k | 22k | 9.63 |
